TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07533708: A Phase Ia Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX3902 (a STEAP1xCD3xCD28 Trispecific Antibody) in Patients With Metastatic Castration-Resistant Prostate Cancer and

Sponsor: Shanghai Henlius Biotech · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 48 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$6,723,024

Rescue Site Savings

+$4,429,656

Unlock Full NCT07533708 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07533708 Rescue Dossier →